Relationship between Mutations of KRAS，NRAS and BRAF Genes and Colorectal Liver Metastases

Haimei GOU; Li FANG; Xiaowu ZHONG

doi:10.12259/j.issn.2095-610X.S20230106

Volume 44 Issue 1

Jan. 2023

Turn off MathJax

Article Contents

Abstract

References

Relative Articles

Article Navigation > Journal of Kunming Medical University > 2023 > 44(1): 19-24

Haimei GOU, Li FANG, Xiaowu ZHONG. Relationship between Mutations of KRAS，NRAS and BRAF Genes and Colorectal Liver Metastases[J]. Journal of Kunming Medical University, 2023, 44(1): 19-24. doi: 10.12259/j.issn.2095-610X.S20230106

Citation:

Haimei GOU, Li FANG, Xiaowu ZHONG. Relationship between Mutations of KRAS，NRAS and BRAF Genes and Colorectal Liver Metastases[J]. Journal of Kunming Medical University, 2023, 44(1): 19-24. doi: 10.12259/j.issn.2095-610X.S20230106

Citation:

PDF( 596 KB)

Relationship between Mutations of KRAS，NRAS and BRAF Genes and Colorectal Liver Metastases

doi: 10.12259/j.issn.2095-610X.S20230106

Haimei GOU^{1, 2},
Li FANG^{1, 2},
Xiaowu ZHONG^{1, 2, 3
,
,}

1.
Dept. of Clinical Laboratory，The Affiliated Hospital of North Sichuan Medical College，Nanchong Sichuan 637000
2.
Dept. of Laboratory Medicine
3.
Translational Medicine Research Center，North Sichuan Medical College，Nanchong Sichuan 637007，China

Received Date: 2022-10-26
Available Online: 2022-12-24
Publish Date: 2023-01-18

Abstract

Abstract

Objective To investigate the relationship between KRAS, NRAS and BRAF gene mutations and liver metastasis in colorectal cancer. Methods A total of 246 colorectal cancer tissue specimens were collected from the Affiliated Hospital of North Sichuan Medical College from January 2019 to October 2021. KRAS, BRAF and PIK3CA mutations analysis were performed with ARMS method and fluorescence PCR technology. Clinical data were collected and the relationship between KRAS, NRAS and BRAF gene mutations and liver metastasis were analyzed. Results The mutation rates of KRAS, NRAS and BRAF were 45.93% （113/246）, 6.10% （15/246） and 4.87% （12/246） in 246 colorectal cancer cases, respectively. NRAS gene mutation was associated with synchronous colorectal liver metastasis. The frequency of liver metastasis was higher in the NRAS mutation group at the time of colorectal cancer diagnosis （P = 0.005）, but there was no significant difference in the frequency of liver metastasis within 1a between the NRAS mutant group and the wild group as the disease progresses （P = 0.155）. Multivariate Logistic regression analysis showed that NRAS mutation was an independent risk factor for synchronous colorectal cancer liver metastasis （OR = 9.974, P = 0.008）. KRAS and BRAF mutations had no significant correlation with liver metastasis （P > 0.05）. Conclusion Colorectal cancer patients with NRAS gene mutation are prone to liver metastasis in the early stage. NRAS gene mutation detection not only plays an important role in targeted therapy, but also in the early evaluation of liver metastasis.
- Colorectal cancer,
- Liver metastasis,
- KRAS,
- NRAS,
- BRAF

FullText(HTML)

References(18)

References

[1]	Bray F,Ferlay J,Soerjomataram I,et al. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424. doi: 10.3322/caac.21492
[2]	Siegel R L,Miller K D,Fedewa S A,et al. Colorectal cancer statistics,2017[J]. CA Cancer J Clin,2017,67(3):177-193. doi: 10.3322/caac.21395
[3]	朱德祥,任黎,许剑民. 中国结直肠癌肝转移诊断和综合治疗指南(2020版)[J]. 中国实用外科志,2021,41(1):1-11.
[4]	Zhou J,Ji Q,Li Q. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies[J]. J Exp Clin Cancer Res,2021,40(1):328. doi: 10.1186/s13046-021-02130-2
[5]	Taieb J,Le Malicot K,Shi Q,et al. Prognostic value of BRAF and KRAS mutations in MSI and MSS stage Ⅲ colon cancer[J]. J Natl Cancer Inst,2016,109(5):djw272.
[6]	Dolatkhah R,Dastgiri S,Eftekhar Sadat A T,et al. Impact of RAS/RAF mutations on clinical and prognostic outcomes in metastatic colorectal cancer[J]. Bioimpacts,2021,11(1):5-14.
[7]	Guo T A,Wu Y C,Tan C,et al. Clinicopathologic features and prognostic value of KRAS,NRAS and BRAF mutations and DNA mismatch repair status: A single-center retrospective study of 1,834 Chinese patients with Stage I-IV colorectal cancer[J]. Int J Cancer,2019,145(6):1625-1634. doi: 10.1002/ijc.32489
[8]	《结直肠癌分子生物标志物检测专家共识》编写组. 结直肠癌分子生物标志物检测专家共识[J]. 中华病理学杂志,2018,47(4):237.
[9]	Benson A B,Venook A P,Al-Hawary M M,et al. NCCN guidelines insights:Colon cancer,version 2.2018[J]. J Natl Compr Canc Netw,2018,16(4):359-369. doi: 10.6004/jnccn.2018.0021
[10]	Tong G J,Zhang G Y,Liu J,et al. Comparison of the eighth version of the American Joint Committee on Cancer manual to the seventh version for colorectal cancer: A retrospective review of our data[J]. World J Clin Oncol,2018,9(7):148-161. doi: 10.5306/wjco.v9.i7.148
[11]	白杨,吴林林,安建多,等. 结直肠癌组织中KRAS、NRAS、BRAF、PIK3CA基因突变与临床病理特征及MMR蛋白、p53蛋白表达的相关性研究[J]. 诊断病理学杂志,2021,28(3):183-188,193.
[12]	朱凤伟,吕亚莉,钟梅,等. 423例结直肠癌KRAS/NRAS/BRAF/PIK3CA基因突变与临床病理的关系分析[J]. 解放军医学院学报,2019,40(10):976-980.
[13]	De Roock W,Claes B,Bernasconi D,et al. Effects of KRAS,BRAF,NRAS,and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis[J]. Lancet Oncol,2010,11(8):753-762. doi: 10.1016/S1470-2045(10)70130-3
[14]	Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer[J]. Nature,2012,487(7407):330-337. doi: 10.1038/nature11252
[15]	Spella M,Marazioti A,Arendt KAM,et al. RAS oncogenes direct metastasis[J]. Mol Cell Oncol,2017,4(5):e1345711. doi: 10.1080/23723556.2017.1345711
[16]	Giannou A D,Marazioti A,Kanellakis N I,et al. NRAS destines tumor cells to the lungs[J]. EMBO Mol Med,2017,9(5):672-686. doi: 10.15252/emmm.201606978
[17]	Adler N R,Wolfe R,Kelly J W,et al. Tumour mutation status and sites of metastasis in patients with cutaneous melanoma[J]. Br J Cancer,2017,117(7):1026-1035. doi: 10.1038/bjc.2017.254
[18]	Tie J,Lipton L,Desai J,et al. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer[J]. Clin Cancer Res,2011,17(5):1122-1130. doi: 10.1158/1078-0432.CCR-10-1720

Relative Articles(20)

Relative Articles

[1]	Bo LIU, Qiaolian WU, Quanchang ZHANG. The Effects of the Laparoscopic and Open Surgery on the Postoperative Intestinal Function Recovery Time in Elderly Patients with Colorectal Cancer. Journal of Kunming Medical University, 2024, 45(1): 143-148. doi: 10.12259/j.issn.2095-610X.S20240124
[2]	Zhaoyang CAO, Sijia LIU, Yaying YANG. Advancements of Radiomics in Coloractal Cancer. Journal of Kunming Medical University, 2024, 44(1B): 1-7.
[3]	Yuan WANG, Rong LI, Jiaojiao CHEN, Yanli SHEN, Fengdi HU. Clinical Value of Fecal SDC2 Gene Methylation Detection in Early Screening of Colorectal Cancer. Journal of Kunming Medical University, 2023, 44(5): 138-143. doi: 10.12259/j.issn.2095-610X.S20230524
[4]	Jiang WU, He MA, Jinyun JIANG, Na LIU, Ruihuan ZHAO, Yuefeng HE. The Relationship between Arsenic Exposure and DNA Damage of EGFR，PTEN，Kras，and PIK3CA Genes in Arsenic Factory Workers. Journal of Kunming Medical University, 2023, 44(7): 29-33. doi: 10.12259/j.issn.2095-610X.S20230717
[5]	Yan LIANG, Lei WANG, Ming LEI, Benchao CHEN, Ping SUN, Shuai LI, Li LIU, Qianrong WANG, Manlin LIAO, Qianli MA. Correlation between KRAS Gene Polymorphism and Non-small Cell Lung Cancer in Yunnan Han Population. Journal of Kunming Medical University, 2023, 44(2): 52-60. doi: 10.12259/j.issn.2095-610X.S20230210
[6]	Liju ZHANG, Xiaoming JIANG, Changxian CHEN, Xi WU, Zhenyong ZHANG, Weijun LIU. Long Non-coding RNA-p21 Regulates the MicroRNA-9 / Sirtuin-1 Signaling Pathway to Reverse Oxaliplatin Resistance in Colorectal Cancer Cells. Journal of Kunming Medical University, 2022, 43(5): 27-32. doi: 10.12259/j.issn.2095-610X.S20220519
[7]	Helong CHE, Zhijin LI, Keqiang WANG, Weiming QIU, Yi CAO, Laibin LUO. Effect Analysis of Emergency Endoscopic Treatment for Anastomotic Hemorrhage after Colorectal Cancer Resection. Journal of Kunming Medical University, 2022, 43(10): 122-126. doi: 10.12259/j.issn.2095-610X.S20221032
[8]	Yubin LE, Shikui GUO. The Value of Serum Adipokine in the Long-term Prognosis of Colorectal Cancer Patients. Journal of Kunming Medical University, 2022, 43(4): 82-88. doi: 10.12259/j.issn.2095-610X.S20220417
[9]	Zi-hong CHEN, Shi-bo SUN, Xian-mei WANG, Shan-shan YU, Xiu-fang WU, Xiang-shan CHEN, Ting GENG, Hong LIU, Xian-min LIU, Qiong NAN. Abnormal Coagulation Parameters in Patients with Early Colorectal Cancer and Its Clinical Significance. Journal of Kunming Medical University, 2021, 42(5): 96-100. doi: 10.12259/j.issn.2095-610X.S20210518
[10]	Jing-hua LIU, Wei CHANG, Fu-bing YU, Juan SHENG, FENG Cheng-cheng, Ni-shan ZHAO. The Expression of C/EBPδ in Colorectal Cancer and Its Effect on the Proliferation of Cancer Cells. Journal of Kunming Medical University, 2021, 42(9): 57-64. doi: 10.12259/j.issn.2095-610X.S20210913
[11]	Deng Lan Ying , Peng Pai Lan , Liu Yan Ni . . Journal of Kunming Medical University, 2020, 41(09): 125-131.
[12]	Yang Jing Yu , Li Wen Liang . . Journal of Kunming Medical University, 2020, 41(04): 150-156.
[13]	Yang Hong Jun , Wang Xiao Bin , Sun Xiang Hua , Li Zhi Gang . . Journal of Kunming Medical University, 2020, 41(06): 105-108.
[14]	Zhao Min , Zhang Qiang , Ma Yong Ci , Long Fei , Lin Yan Ping , Xu Xue Bin , Zhang Jin Ping . A Clinical Features Analysis of 1 000 Cases of Colorectal Cancer in Yunnan Tumor Hospital. Journal of Kunming Medical University, 2018, 39(05): 90-93.
[15]	Wu Xue Song . . Journal of Kunming Medical University,
[16]	Wang Ruo Tian . . Journal of Kunming Medical University,
[17]	Yang Jian Hua . . Journal of Kunming Medical University,
[18]	Zhong Lin . . Journal of Kunming Medical University,
[19]	Xiao Yun . . Journal of Kunming Medical University,
[20]	Yang Yi Ming . Clinical Experiences in Diagnosis and Treatment of Intestinal Obstruction of 48 Patients with Colorectal Cancer. Journal of Kunming Medical University,

Supplements(0)

Cited By

Cited by

Periodical cited type(27)

1.	谭珂，于艳红，孙娇，孙秀华，王悦，贾琳，邢黎莉，张威. MicroRNA的生物表达与结核病诊断和治疗监测的相关性及其对结核病易感基因表达调控的研究. 中国现代药物应用. 2024(07): 58-61 .
2.	徐红艳，张燕. 养阴祛瘀方辅助治疗对肺结核患者血清血管内皮生长因子、血清干扰素-γ水平及免疫功能的影响. 世界中西医结合杂志. 2023(01): 148-152 .
3.	曹琳，吴晓玲. 乙酰半胱氨酸雾化吸入联合常规抗结核方案治疗重症肺结核的效果及对炎性因子、MALAT1、IP-10、MMP-9水平的影响. 临床医学研究与实践. 2022(05): 34-37 .
4.	冯霭媚. 利福喷丁辅助抗生素对结核病患者免疫功能的影响. 中国实用医药. 2022(25): 23-26 .
5.	刘俊游，石玉林. 克咳片联合四联疗法治疗肺结核的临床疗效观察. 实用中西医结合临床. 2022(24): 12-14+104 .
6.	张瑞霞，陈瑞锋，邓巧娟. 参麦注射液联合HRZE方案治疗肺结核的效果及对XOD、MMP-9水平的影响. 中华中医药学刊. 2021(05): 70-73 .
7.	贾宗岭，单富强，葛国昌，赵幸娜. 微小RNA361-5p在肺结核病人血清中水平及意义. 安徽医药. 2021(08): 1609-1612 .
8.	饶争丽. 含利福喷丁化疗方案治疗肺结核的临床疗效. 临床合理用药杂志. 2020(12): 73-75 .
9.	韦学荣，陈绪坤，李永吉. 黄芪注射液对肺结核患者趋化因子、肾功能及体液免疫水平的影响. 海南医学院学报. 2019(08): 598-601 .
10.	魏桂珍. 胸腺肽α1联合利福布汀治疗复治肺结核的效果观察. 中国疗养医学. 2019(05): 551-552 .
11.	邢小明，许优，李积安. 结核丸联合环丝氨酸治疗耐药性肺结核效果及对患者炎性因子水平的影响. 药物评价研究. 2019(06): 1180-1183 .
12.	魏桂珍. 结核丸联合抗结核化疗治疗肺结核的效果观察. 中国疗养医学. 2019(06): 631-633 .
13.	刘杰. 胸腺五肽联合左氧氟沙星、2HRZE/4HR方案治疗肺结核效果观察. 中国民康医学. 2019(14): 15-17 .
14.	张亚平，岳峰. 胸腺肽联合左氧氟沙星对肺结核患者免疫功能、相关血清指标以及预后质量的影响. 中国合理用药探索. 2019(11): 35-38 .
15.	赵岩. 肺结核患者免疫细胞、凝血功能的改变及临床价值. 中国医药指南. 2019(34): 67-68 .
16.	董振力. 利福喷丁与利福平对肺结核的疗效比较. 河南医学研究. 2018(08): 1484-1485 .
17.	徐红艳. 参麦注射液对肺结核患者血清β-CAR、IL-17及CD4~+细胞表达的影响. 世界中医药. 2018(01): 119-123 .
18.	吴庆国. 利福喷丁治疗新发肺结核疗效及对肝功能的影响. 中国药业. 2018(15): 70-72 .
19.	张英凤. 肺结核患者免疫细胞、炎症因子及凝血功能的变化及意义. 中国实用医药. 2018(08): 40-42 .
20.	曹青，闫抗抗，陈敏纯，薛飞，刘生元. 利福喷丁与利福平在肺结核治疗中的药效比较及安全性探讨. 临床和实验医学杂志. 2018(22): 2424-2427 .
21.	黄彩转，吴丽群，黄远江，周云. 胸腺五肽联合含利福喷丁化疗方案治疗肺结核的临床疗效及其对细胞免疫功能、炎性因子的影响. 实用心脑肺血管病杂志. 2018(09): 96-99 .
22.	胡萍，刘锦程，王启源，姬文兰，高瑜，刘红艳. 2HLZE/4HLE与2HRZE/4HRE抗结核方案在初治菌阳肺结核伴有乙肝患者肝损害中的应用效果. 解放军预防医学杂志. 2018(11): 1378-1380 .
23.	黄政，钟秀珍. 利福喷丁联合左氧氟沙星对复治肺结核病患者化疗效果分析. 青岛医药卫生. 2018(06): 410-412 .
24.	康书慧，张鑫，刘士甫. 利福喷丁治疗肺结核的有效性及安全性. 临床医药文献电子杂志. 2017(90): 17655-17656 .
25.	张晶. 结核药联合利福喷丁对肺结核患者免疫功能、炎症因子、VEGF及MMP-9的影响探讨. 世界最新医学信息文摘. 2017(28): 122+126 .
26.	王曦东. 骨结核所致疼痛以结核丸进行治疗所取得的临床效果研究. 中国医药指南. 2017(31): 218-219 .
27.	张志毕，董超，马娇，冯国华. 丹参水提物对小鼠病理脱发模型毛发的再生影响. 昆明医科大学学报. 2016(11): 23-27 . 本站查看